NILOTINIB
Manner of administration:Oral
Restriction (Streamlined authority code: 17895)
Indication: Chronic Myeloid Leukaemia (CML)
Treatment phase: Continuing treatment - second-line therapy
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 120 | # of repeats: 5 | DPMQ: $3,780.73 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Tasigna | |||||
Manner of administration:Oral
Restriction (Streamlined authority code: 17833)
Indication: Chronic Myeloid Leukaemia (CML)
Treatment phase: Continuing treatment - third-line therapy
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 120 | # of repeats: 5 | DPMQ: $3,780.73 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Tasigna | |||||
Manner of administration:Oral
Restriction (Streamlined authority code: 12549)
Indication: Chronic Myeloid Leukaemia (CML)
Treatment phase: Grandfather treatment for patients initiated with nilotinib 200 mg prior to 1 April
2012 as first-line therapy
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 120 | # of repeats: 5 | DPMQ: $3,780.73 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Tasigna | |||||
Manner of administration:Oral
Restriction
Indication: Chronic Myeloid Leukaemia (CML)
Treatment phase: Initial treatment - third-line therapy
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 120 | # of repeats: 5 | DPMQ: $3,780.73 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Tasigna | |||||
Manner of administration:Oral
Restriction
Indication: Chronic Myeloid Leukaemia (CML)
Treatment phase: Initial treatment - second-line therapy
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 120 | # of repeats: 5 | DPMQ: $3,780.73 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Tasigna | |||||